Bernstein Remains Bullish On HCA Healthcare (HCA); Projects EBITDA Growth Of 2.8% and 4.6% in 2026 And 2027
Key takeaways
- Bernstein Remains Bullish On HCA Healthcare (HCA); Projects EBITDA Growth Of 2.8% and 4.6% in 2026 And 2027 Faheem Tahir Thu, June 11, 2026 at 8:03 PM GMT+7 2 min read HCA HCA Healthcare, Inc.
- (NYSE:HCA) is navigating a cautious macro backdrop for healthcare while continuing to invest in long-term workforce development.
- On June 4, 2026, Bernstein lowered its price target on HCA Healthcare, Inc.
Bernstein Remains Bullish On HCA Healthcare (HCA); Projects EBITDA Growth Of 2.8% and 4.6% in 2026 And 2027 Faheem Tahir Thu, June 11, 2026 at 8:03 PM GMT+7 2 min read HCA HCA Healthcare, Inc. (NYSE:HCA), with a forward P/E of 12.27 and upside potential of 38.4%, is among the top 10 lowest forward P/E stocks in the S&P 500.
HCA Healthcare, Inc. (NYSE:HCA) is navigating a cautious macro backdrop for healthcare while continuing to invest in long-term workforce development.
On June 4, 2026, Bernstein lowered its price target on HCA Healthcare, Inc. (NYSE:HCA) to $413 from $503, keeping a “Market Perform” rating. The firm said it views HCA as much more attractive at current valuation levels but does not expect a near-term catalyst to improve the outlook. Bernstein projects EBITDA growth of 2.8% in 2026 and 4.6% in 2027, citing lower insurance coverage from policy changes and a lack of growth in state-directed payments as the primary headwinds.